IL155238A0 - Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases - Google Patents

Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases

Info

Publication number
IL155238A0
IL155238A0 IL15523801A IL15523801A IL155238A0 IL 155238 A0 IL155238 A0 IL 155238A0 IL 15523801 A IL15523801 A IL 15523801A IL 15523801 A IL15523801 A IL 15523801A IL 155238 A0 IL155238 A0 IL 155238A0
Authority
IL
Israel
Prior art keywords
compositions
methods
risk factors
cardiovascular diseases
lowering plasma
Prior art date
Application number
IL15523801A
Other languages
English (en)
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of IL155238A0 publication Critical patent/IL155238A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
IL15523801A 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases IL155238A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718600P 2000-10-03 2000-10-03
PCT/US2001/031203 WO2002028379A2 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases

Publications (1)

Publication Number Publication Date
IL155238A0 true IL155238A0 (en) 2003-11-23

Family

ID=22892673

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15523801A IL155238A0 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases
IL185384A IL185384A (en) 2000-10-03 2007-08-20 Pharmacological compositions for lowering plasma lipoprotein (A) levels and lowering risk factors for cardiovascular disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL185384A IL185384A (en) 2000-10-03 2007-08-20 Pharmacological compositions for lowering plasma lipoprotein (A) levels and lowering risk factors for cardiovascular disease

Country Status (24)

Country Link
US (2) US6693129B2 (ro)
EP (1) EP1324753A2 (ro)
JP (1) JP2004525080A (ro)
KR (1) KR20030070003A (ro)
CN (1) CN100421659C (ro)
AU (2) AU2002211452B2 (ro)
BR (1) BR0114526A (ro)
CA (1) CA2424880A1 (ro)
CZ (1) CZ20031167A3 (ro)
EE (1) EE200300136A (ro)
HR (1) HRP20030348A2 (ro)
HU (1) HUP0303040A3 (ro)
IL (2) IL155238A0 (ro)
MX (1) MXPA03002964A (ro)
NO (1) NO20031510L (ro)
NZ (2) NZ545806A (ro)
PL (1) PL212479B1 (ro)
RO (1) RO120567B1 (ro)
RU (1) RU2289406C2 (ro)
SK (1) SK5252003A3 (ro)
TR (1) TR200300594T2 (ro)
UA (1) UA77660C2 (ro)
WO (1) WO2002028379A2 (ro)
ZA (1) ZA200302772B (ro)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100369605C (zh) * 2000-12-14 2008-02-20 三共株式会社 血液脂质改善剂组合物
CA2438063A1 (en) * 2001-02-27 2002-09-06 Nutrition 21, Inc. Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
US20030054978A1 (en) * 2001-08-31 2003-03-20 Babish John G. Arginine compositions for coordinate modification of multiple cardiovascular risk factors
JP2006501224A (ja) 2002-08-22 2006-01-12 ニュートリション ２１、インコーポレイテッド アルギニンケイ酸塩イノシトール複合体およびその使用
US7635469B2 (en) * 2002-08-28 2009-12-22 Premier Micronutrient Corporation Micronutrient formulations for hearing health
US20080020035A1 (en) * 2002-08-28 2008-01-24 Kedar Prasad Micronutrient formulations and related methods of manufacture
JP2006514100A (ja) * 2002-10-24 2006-04-27 イーノス・ファーマシューティカルス・インコーポレーテッド 徐放性ｌ−アルギニン製剤並びに製造方法および使用方法
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
CA2540202A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
JP2005225871A (ja) * 2004-01-16 2005-08-25 Sankyo Co Ltd 血中トリグリセライド又はホモシステインを低下させる医薬組成物
CA2572815A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
JP4896531B2 (ja) * 2005-01-25 2012-03-14 第一三共ヘルスケア株式会社 血中ＣｏＱ１０量を増加させる医薬組成物
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
KR100592719B1 (ko) * 2005-10-05 2006-06-28 케이에스엠기술 주식회사 하천의 생태계 보호용 이물질 유입방지 시설
US20070292493A1 (en) * 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US20080207748A1 (en) * 2007-02-22 2008-08-28 Innovation Labs, Inc. Vitamin c preparation
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2008139314A1 (en) * 2007-05-11 2008-11-20 Horphag Research (Luxembourg) Holding Sa Compositions and methods for treating joint disorders
US7867524B2 (en) * 2007-10-05 2011-01-11 David Rowland Energizing formulation
RU2377007C1 (ru) * 2008-06-23 2009-12-27 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М" Средство для лечения и профилактики онкологических заболеваний и способ применения этого средства (варианты)
RU2385722C1 (ru) * 2008-07-02 2010-04-10 Тимофей Георгиевич Кожока Фармацевтическая нейропротекторная, антиоксидантная, антигипоксантная, антиапоптотическая и мембранопротекторная композиция и способ лечения
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
RU2468791C2 (ru) * 2011-02-24 2012-12-10 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием
EA025844B1 (ru) * 2012-05-08 2017-02-28 Общество С Ограниченной Ответственностью "Лигур-М" Средство для коррекции гиперхолестеринемии
EP3160459A1 (en) * 2014-06-24 2017-05-03 Dedraf Holding B.V. New mineral composition
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
US11344575B2 (en) 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
CN109890384A (zh) 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
EP3398601A1 (en) * 2017-05-02 2018-11-07 Salmon Pharma GmbH Nicotinamide for treating dyslipidemia
CN108033939B (zh) * 2017-12-26 2020-09-11 上海共晶医药科技有限公司 生育酚与脯氨酸的共结晶及其制备方法
CN109092262B (zh) * 2018-08-28 2019-07-05 广州达济医学科技有限公司 低密度脂蛋白吸附微球及制备方法和吸附材料
CA3118583C (en) 2018-11-02 2024-05-14 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
EP3883558A1 (en) * 2018-12-26 2021-09-29 Colgate-Palmolive Company Specific co-aggregation inhibition by arginine
IL294021A (en) 2019-12-16 2022-08-01 Nutrition 21 Llc Methods of production of arginine-silicate complexes
AU2023300565A1 (en) * 2022-07-01 2024-12-12 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma
IT202300020718A1 (it) * 2023-10-06 2025-04-06 Promin Prod Di Medicina Integrata S R L Composizione a base di inositolo e proantocianidine oligomeriche

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356370A (en) * 1972-03-06 1974-06-12 Howard A N Methods and formulations for the treatment of obesity
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4891220A (en) 1988-07-14 1990-01-02 Immudyne, Inc. Method and composition for treating hyperlipidemia
US5268181A (en) 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
KR19980703596A (ko) * 1990-10-01 1998-12-05 쉘비 캘버트 모스 주요 혈관 이상 상태를 억제하기 위한 베타-카로틴 및 비타민 e 치료법
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6361800B1 (en) * 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
DE60027415T2 (de) * 2000-06-16 2006-10-19 Rath, Matthias, Dr.med. Zusammensetzung für die Verhinderung der Glattmuskelkrankheiten, die Ascorbat, Arginin und Magnesium enthält
ES2261136T3 (es) * 2000-10-09 2006-11-16 Matthias Dr. Med. Rath Composicion terapeutica de ascorbato con lisina y arginina para prevencion y tratamiento del cancer.
US6974833B2 (en) * 2001-01-16 2005-12-13 Matthias Rath Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration
US7056950B2 (en) * 2001-02-14 2006-06-06 Matthias Rath Compositions of biochemical compounds involved in bioenergy metabolism of cells
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells

Also Published As

Publication number Publication date
BR0114526A (pt) 2005-04-26
RO120567B1 (ro) 2006-04-28
CN100421659C (zh) 2008-10-01
HUP0303040A3 (en) 2005-05-30
WO2002028379A3 (en) 2003-02-27
HUP0303040A2 (hu) 2003-12-29
NO20031510L (no) 2003-06-02
JP2004525080A (ja) 2004-08-19
ZA200302772B (en) 2004-10-18
NZ545806A (en) 2008-04-30
NO20031510D0 (no) 2003-04-03
IL185384A (en) 2008-06-05
PL365986A1 (en) 2005-01-24
TR200300594T2 (tr) 2004-10-21
NZ525390A (en) 2006-04-28
WO2002028379A2 (en) 2002-04-11
US6693129B2 (en) 2004-02-17
US7244749B2 (en) 2007-07-17
PL212479B1 (pl) 2012-10-31
EP1324753A2 (en) 2003-07-09
HRP20030348A2 (en) 2005-06-30
AU2002211452B2 (en) 2005-10-27
MXPA03002964A (es) 2004-12-06
CN1477959A (zh) 2004-02-25
EE200300136A (et) 2003-08-15
AU1145202A (en) 2002-04-15
CA2424880A1 (en) 2002-04-11
US20040157895A1 (en) 2004-08-12
US20020094996A1 (en) 2002-07-18
UA77660C2 (en) 2007-01-15
CZ20031167A3 (cs) 2003-12-17
KR20030070003A (ko) 2003-08-27
RU2289406C2 (ru) 2006-12-20
SK5252003A3 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
AU1145202A (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160648A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL152753A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
NZ514350A (en) Compositions and methods for effecting the levels of cholesterol
EP1333825A4 (en) IMPROVED OXYBUTYNIN DELIVERY TECHNIQUE AND COMPOSITIONS THEREOF
SG94728A1 (en) Method of cutting csp substrates
GB0103871D0 (en) Bleaching composition of enhanced stability and a process for making such a composition
AU2002366809A8 (en) Syn3 compositions and methods
EP1292305A4 (en) METHOD FOR INHIBITING DOPAMINE USING L-THREO-METHYLPHENIDATE
IL162140A0 (en) Method for the preparation of l-alpha-fluoro corticosteroids
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
AU2002364911A1 (en) Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use
IL129220A0 (en) A pharmaceutical composition for lowering plasma levels of lipoprotein (a)
AU2002305574A1 (en) Compositions comprising d-chiro inositol and lipid lowering compounds and methods of treatment thereof
AU2003246872A1 (en) Process for the preparation of compositions and apparatus embodying the process
AU2001215597A1 (en) Method of fractionating capillaries-containing material
AU2001276162A1 (en) A method of stabilisation and compositions for use therein
AUPQ899400A0 (en) A method of stabilisation and compositions for use therein
AU2002316387A1 (en) Nmp35 apoptosis inhibitor gene disruptions compositions and methods related thereto
AU6859201A (en) Inhibition of lipoprotein secretion
IL135447A0 (en) Composition for treatment of bronchial asthma
AU2002316420A1 (en) Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma
AU2002236171A1 (en) Method for induction of genome instability